Goldman Sachs’s Nephros NEPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$42.2K Sell
14,163
-4,817
-25% -$19.2K ﹤0.01% 6308
2025
Q4
$92.6K Buy
18,980
+337
+2% +$1.72K ﹤0.01% 6200
2025
Q3
$88.2K Buy
+18,643
New +$73.2K ﹤0.01% 6099
2019
Q4
Sell
-19,418
Closed -$156K 5348
2019
Q3
$156K Buy
+19,418
New +$142K ﹤0.01% 4886

Other funds holding NEPH

Goldman Sachs's NEPH Position: Q1 2026 in Review

Goldman Sachs reduced its Nephros (NEPH) stake by 25% in Q1 2026, selling an estimated $19.2K and leaving 14,163 shares worth $42.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6308.

Goldman Sachs first reported a position in NEPH in Q3 2019 and has held it in 4 quarters since. The position peaked at $156K in Q3 2019. 27 funds tracked by Wall St. Rank hold NEPH as of Q1 2026.

  • Goldman Sachs held 14,163 shares of Nephros worth $42.2K as of Q1 2026.
  • Goldman Sachs sold 4,817 Nephros shares in Q1 2026, an estimated $19.2K.
  • Nephros made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6308 holding.
  • Goldman Sachs first reported a position in Nephros in Q3 2019 and has held it in 4 quarters since.
  • Goldman Sachs's Nephros position peaked at $156K in Q3 2019.
  • 27 funds tracked by Wall St. Rank held Nephros as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.